Investment
Features
FeesSafety
Academy
More
Pluang+

Compare DuPont de Nemours Inc (DD) vs Medpace Holdings Inc (MEDP) Price & Performance

DuPont de Nemours IncTrade
Medpace Holdings IncTrade

Price performance (Past 24H)

Key statistics

DuPont de Nemours Inc vs Medpace Holdings Inc — how do they compare? DuPont de Nemours Inc trades at $144.26 (market cap $19.12B), while Medpace Holdings Inc trades at $605.78 (market cap $16.81B). The key difference: DuPont de Nemours Inc and Medpace Holdings Inc are close in size by market cap, and DuPont de Nemours Inc pays a 1.7% dividend while Medpace Holdings Inc pays none. Which is the better fit depends on your goals.

DDMEDP
Market Cap
$19.12B$16.81B
Sector
Basic MaterialsTechnology
52-Week High
$154.59$620.59
52-Week Low
$90.24$393.42
Enterprise Value
$20.50B$16.43B
Dividend Yield
1.7%

Aura AI Summary

Signals from Pluang's Aura AI — not financial advice

DuPont de Nemours Inc

DuPont (DD) trades at $142.48, down 1.06% on the day, with a bullish technical signal from moving averages and strong analyst support. The company reported Q2 2026 earnings that beat expectations, with EPS of $1.88 versus $1.76 expected, and raised its full-year 2026 outlook, driven by healthcare, industrial water, and aerospace demand. However, 2025 fundamentals show a net loss of $779 million on revenue of $6.85 billion, with a high P/E ratio of 61.15 indicating premium valuation.

The outlook is cautiously optimistic, supported by earnings momentum and innovation awards, but risks include ongoing legal settlements over PFAS chemicals and thin net margins. The consensus price target of $232.80 suggests significant upside potential if operational improvements continue.

Medpace Holdings Inc

MEDP trades at $590.67, up 0.97% on the day, near its consensus price target of $599.57. The stock shows bullish momentum with a golden cross formation and strong institutional interest, while recent Q2 2026 earnings beat estimates with EPS of $4.25 versus $3.98 expected. Revenue growth remains robust, projected to rise from $2.53 billion in 2025 to $2.8 billion in 2026, supporting a premium valuation with a P/E of 35.4.

Outlook is positive given earnings consistency and raised 2026 guidance, but risks include high valuation sensitivity and a shareholder lawsuit investigation. The stock offers growth potential from a strong backlog and net book-to-bill ratio of 1.13x, though investors should monitor legal developments and competitive pressures in medical services.

Returns comparison

Trailing returns across standard periods

Top news

Latest headlines on both assets

About DuPont de Nemours Inc

DuPont is a diversified global specialty chemicals company created in 2019 as a result of the DowDuPont merger and subsequent separations. Its portfolio includes specialty chemicals and downstream products that serve the electronics and communication, automotive, construction, safety and protection, and water management industries. DuPont benefits from the ability to produce patented specialty chemicals that command pricing power. Noteworthy products include Kevlar, Tyvek, and Nomex have evolved over time to enable a wide range of applications across multiple industries.

Read more on DD

About Medpace Holdings Inc

Medpace Holdings, Inc. is a full-service clinical contract research organization (CRO) that provides comprehensive and scientifically-driven clinical development services to the biotechnology, pharmaceutical, and medical device industries. The company specializes in conducting global clinical trials for new drug and medical device approvals. Medpace's model emphasizes therapeutic expertise and a highly integrated approach to accelerate the clinical development process for its clients.

Read more on MEDP